VG Life Sciences Company

VG Life Sciences discovers and develops drug therapies for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
VG Life Sciences aims to improve and save lives through the development of transformative therapies for drug-resistant cancers and autoimmune diseases.
We are moving forward to achieve our vision through the research and development of drugs using two platform technologies, Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT).
Our efforts on our revolutionary TPT drug, VG1177, for which we were issued a composition-of-matter patent (Patent No: US 8,957,031), are focused on accelerating progression from the research laboratory, to pre-clinical studies, and to clinical trials. The VG1177 peptide prevents the survival of pro-inflammatory cells that give rise to autoimmune diseases and other disorders.
We have completed a pre-investigational new drug meeting with the FDA (IND # 110820) and initiated preclinical work in November 2013 with our animal safety and toxicity study, a prerequisite for clinical trials.
Technology: Personalised Medicine
Industry: P4 Medicine
Headquarters: United States
Founded Date: 1995
Employees Number: 11-50
Funding Status: IPO
Investors Number: 1
Total Funding: $2.8M
Estimated Revenue: Less than $1M
Last Funding Type: Post-IPO Equity

Visit Website
info@vglifesciences.com
http://twitter.com/VGlifesciences
Register and Claim Ownership